Navigation Links
Lucintel Profiles Leaders in Generic Drugs Industry: Global Market Expected to Reach US $335.8 Billion in 2017

Irving, TX (PRWEB) May 14, 2013

Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The global generic drugs industry experienced average growth over the last five years and is expected to reach approximately US $335.8 billion in 2017.

Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the global generic drugs companies and presents its findings in “Top Five Global Generic Drug Companies Performance, Strategies, and Competitive Analysis.” The report provides detailed insight into the performance of the top five generic drug companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.

The fragmented generic drugs industry includes producers of medications whose patent or marketing rights have expired. The industry includes drugs from all therapeutic areas: central nervous system, cardiovascular drugs, oncology drugs, and others. A combination of factors such as technology innovations, patent expiration, aging population, and changing lifestyles substantially affect market dynamics. In this study, Lucintel profiles the following five companies with detailed competitive assessments:

  •     Abbott Laboratories             
  •     Mylan Inc.                                                
  •     Novartis AG                        
  •     Teva Pharmaceuticals Ind. Ltd.    
  •     Watson Pharmaceuticals Inc        

As indicated in Lucintel’s study, the Asia Pacific (APAC) region holds good growth potential. India is expected to play an increasing role in the global economy as demand from a growing population continues to drive consumption for generic drugs. Major pharmaceuticals companies are planning to invest in the Asian markets to gain the market share for generic drugs.

This medical market report provides industry leaders with a competitive benchmarking of the world’s top five generic drug companies. The study provides up-to-date information on the market share, profit margins, capabilities, and business strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis, and insight, critical to the development and implementation of effective marketing and sales plans.

For a detailed table of contents and pricing information on this timely, insightful report, contact Lucintel at +1-972-636-5056 or via email at helpdesk(at)lucintel(dot)com. Lucintel provides cutting-edge decision support services that facilitate critical decisions with greater speed, insight, M & A due diligence and cost efficiency. To learn more, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lucintel Estimates Global Home Healthcare Device Industry Reach US $29 Billion in 2017
2. Lucintel Report Outlines $100 Billion Market for Global Oncology Drugs Industry in 2018
3. CodingCertification.Org in the Top 5 Percent in LinkedIn Most Viewed Profiles in 2012
4. Global cardiology leaders meet in Dubai
5. Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology
6. Leaders in childrens health to gather in Boston
7. Chinese Drywall Complaint Center Now Demands Leadership From Obama & EPA, For Homeowners In Florida And In The US Southeast Stuck In Toxic Chinese Drywall Hell-Forward?
8. UCLA School of Dentistry gets $5M from NIH to train future leaders in oral health research
9. A breath of fresh air: Childhood Asthma Leadership Coalition launches
10. College biology faculty named Leadership Fellows
11. UC Riverside Biologist named a Leadership Fellow
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: